Evidence map›Paper›PMID 37284060›Full record

ArticleJournal of market access & health policy2023

The role of stakeholder involvement in the evolving EU HTA process:

Lauren Van Haesendonck, Jörg Ruof, Thomas Desmet, Walter Van Dyck, Steven Simoens, Isabelle Huys, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks and 13 more

Abstract read
In one paragraph

Article in Journal of market access & health policy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Getting fairer over time? Assessing changes in health technology funding processes using the accountability for reasonableness (A4R) framework.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  3. Article
  4. Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Paving the road for a successful EU HTA Reform implementation.Global & regional health technology assessment
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Lauren Van HaesendonckDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Jörg Ruofr-connect Ltd, Basel, Switzerland.
Thomas DesmetDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Walter Van DyckHealthcare Management Centre, Vlerick Business School, Brussels, Belgium.
Steven SimoensDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Isabelle HuysDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Rosa GiulianiGuy's and St Thomas' NHS Foundation Trust, London, UK.
Mondher ToumiFaculty of Medicine, Public Health Department, Aix-Marseille University, Marseille, France.
Christian DierksDierks+Company, Berlin, Germany.
Juliana DierksDierks+Company, Berlin, Germany.
Antonella CardoneCancer Patients Europe Brussels, Belgium.
Francois HouÿezEuropean Organisation for Rare Diseases (EURORDIS), Paris, France.
Mira PavlovicMedicines Development and Training (MDT) Services, Paris, France.
Michael BerntgenScientific Evidence Generation department, European Medicines Agency (EMA), Amsterdam, The Netherlands.
Peter G M MolDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands.
Anja SchielNorwegian Medicines Agency (NOMA), Oslo, Norway.
Wim GoettschNational Health Care Institute, Diemen, The Netherlands.
Fabrizio GianfrateUniversity of Ferrara, Ferrara, Italy.
Stefano CapriHealth Economics and Payer Evidence, Astra Zeneca, Cambridge, UK.
James RyanGlobal Market Access & Pricing, Abbvie AG, Cham, Switzerland.
Pierre DucournauHiTT Foundation, International University of Catalonia-UIC, Barcelona, Spain.
Oriol Solà-MoralesUtrecht Centre for Pharmaceutical Policy, Division of Pharmacoepidemiology and Clinical Pharmacology, University of Utrecht, Utrecht, The Netherlands.
Elaine Julianr-connect Ltd, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Involvement of all relevant stakeholders will be of utmost importance for the success of the developing EU HTA harmonization process. A multi-step procedure was applied to develop a survey across stakeholders/collaborators within the EU HTA framework to assess their current level of involvement, determine their suggested future role, identify challenges to contribution, and highlight efficient ways to fulfilling their role. The 'key' stakeholder groups identified and covered by this research included: patients', clinicians', regulatory, and Health Technology Developer representatives. The survey was circulated to a wide expert audience including all relevant stakeholder groups in order to determine self-perception by the 'key' stakeholders regarding involvement in the HTA process (self-rating), and in a second, slightly modified version of the questionnaire, to determine the perception of 'key' stakeholder involvement by HTA bodies, payers, and policymakers (external rating). Predefined analyses were conducted on the submitted responses. Fifty-four responses were received (patients 9; clinicians: 8; regulators: 4; HTDs 14; HTA bodies: 7; Payers: 5; policymakers 3; others 4). The mean self-perceived involvement score was consistently lower for each of the 'key' stakeholder groups than the respective external ratings. Based on the qualitative insights generated in the survey, a RACI Chart (Responsible/Accountable/Consulted/Informed) was developed for each of the stakeholder groups to determine their roles and involvement in the current EU HTA process. Our findings suggest extensive effort and a distinct research agenda are required to ensure adequate involvement of the key stakeholder groups in the evolving EU HTA process.

Indexed as

EUHTAHealth policyHealth technology assessmentStakeholder involvement

Identifiers

PMID37284060
PMCPMC10240997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.